Background. The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes. Prior studies have shown large between-patient variability in albuminuria treatment response. We previously developed and validated a urinary proteomic classifier that predicts onset and progression of chronic kidney disease. Here, we tested whether the proteomic classifier based on 273 urinary peptides (CKD273) predicts albuminuria response to spironolactone treatment. Methods. We performed a post hoc analysis in a double-blind randomized clinical trial with allocation to either spironolactone 12.5-50 mg/day (n ¼ 57) or placebo (n ¼ 54) for 16 weeks. Patients were diagnosed with type 2 diabetes and resistant hypertension. Treatment was an adjunct to renin-angiotensin system inhibition. Primary endpoint was the percentage change in urine albumin to creatinine ratio (UACR). Capillary electrophoresis mass spectrometry was used to quantify urinary peptides at baseline. The previously validated combination of 273 known urinary peptides was used as proteomic classifier. Results. Spironolactone reduced UACR relative to placebo by 50%, although with a large between-patient variability in UACR response (5th to 95th percentile, 7 to 312%). An interaction was detected between CKD273 and treatment assignment (b ¼ À1.09, P ¼ 0.026). Higher values of CKD273 at baseline were associated with a larger reduction in UACR in the spironolactone group (b ¼ À0.70, P ¼ 0.049), but not in the placebo group (b ¼ 0.39, P ¼ 0.25). Stratified in tertiles of baseline CKD273, reduction in UACR was greater in the highest tertile, 63% (95% confidence interval: 35-79%), as compared with the two other tertiles combined, 16% (À17 to 40%) (P ¼ 0.011). Conclusions. A urinary proteomics classifier can be used to identify individuals with type 2 diabetes who are more likely to
A B S T R A C T
Background. The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes. Prior studies have shown large between-patient variability in albuminuria treatment response. We previously developed and validated a urinary proteomic classifier that predicts onset and progression of chronic kidney disease. Here, we tested whether the proteomic classifier based on 273 urinary peptides (CKD273) predicts albuminuria response to spironolactone treatment. Methods. We performed a post hoc analysis in a double-blind randomized clinical trial with allocation to either spironolactone 12.5-50 mg/day (n ¼ 57) or placebo (n ¼ 54) for 16 weeks. Patients were diagnosed with type 2 diabetes and resistant hypertension. Treatment was an adjunct to renin-angiotensin system inhibition. Primary endpoint was the percentage change in urine albumin to creatinine ratio (UACR). Capillary electrophoresis mass spectrometry was used to quantify urinary peptides at baseline. The previously validated combination of 273 known urinary peptides was used as proteomic classifier. Results. Spironolactone reduced UACR relative to placebo by 50%, although with a large between-patient variability in UACR response (5th to 95th percentile, 7 to 312%). An interaction was detected between CKD273 and treatment assignment (b ¼ À1.09, P ¼ 0.026). Higher values of CKD273 at baseline were associated with a larger reduction in UACR in the spironolactone group (b ¼ À0.70, P ¼ 0.049), but not in the placebo group (b ¼ 0.39, P ¼ 0.25). Stratified in tertiles of baseline CKD273, reduction in UACR was greater in the highest tertile, 63% (95% confidence interval: 35-79%), as compared with the two other tertiles combined, 16% (À17 to 40%) (P ¼ 0.011). Conclusions. A urinary proteomics classifier can be used to identify individuals with type 2 diabetes who are more likely to show an albuminuria-lowering response to spironolactone treatment. These results suggest that urinary proteomics may be a valuable tool to tailor therapy, but confirmation in a larger clinical trial is required.
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I N T R O D U C T I O N
Blockade of the renin-angiotensin-aldosterone system (RAAS) is a cornerstone in the treatment of diabetes-related complications. RAAS inhibition with mineralocorticoid receptor antagonists (MRA) has been particularly effective in slowing the progression of renal function decline and reducing blood pressure and albuminuria [1, 2] . However, a well-acknowledged concern with MRA therapy is the rise in potassium levels potentially leading to life-threatening hyperkalaemia [3] . Hyperkalaemia during RAAS inhibition is more likely in patients with diabetes and/or renal impairment [4] .
The individual response to MRA therapy regarding albuminuria and serum potassium shows a large variability between individuals [5, 6] . Understanding the individual variability in response to MRAs on albuminuria and serum potassium may facilitate more targeted interventions and ensure the efficacious and safe use in patients with diabetes.
The measurement of peptides in biological fluids has emerged as a potential tool to discover novel markers that may help to identify subjects at risk for chronic kidney disease (CKD), or monitor drug effect [7, 8] . A proteomic classifier based on 273 specific urine peptides (CKD273) has been associated with more advanced diabetic nephropathy. The classifier contains peptides that have been associated with renal pathophysiology and linked to progression of tubulointerstitial fibrosis [9] [10] [11] [12] . Previous studies have shown that MRAs exert anti-fibrotic effects [13] . Hence, we hypothesize that the response to MRA may be more pronounced in patients with a larger degree of fibrosis reflected by a higher level of the CKD273 classifier.
Therefore, the aim of this study was to assess whether the CKD273 score predicts the response in albuminuria to the MRA spironolactone.
M A T E R I A L S A N D M E T H O D S

Study population
This study is a secondary analysis of a randomized doubleblind, placebo-controlled trial. The study population, study design and main outcomes have been previously described [14] . In brief, patients included were diagnosed with resistant hypertension (based on guidelines from the European Society of Hypertension) and type 2 diabetes with an age ranging from 18 to 75 years. At baseline, patients were randomly assigned to double-blind treatment with spironolactone or matching placebo. Study drug treatment was initiated with one tablet of 25 mg and up-titrated to 50 mg if the blood pressure target of 130 mmHg systolic or 80 mmHg diastolic was not achieved. Physicians were allowed to down-titrate to 12.5 mg in case of plasma potassium levels >5.0 mmol/L or hypotension. If plasma potassium level rose >5.5 mmol/L study medication was discontinued. A number of 119 participants were randomized. Four were discontinued in the spironolactone group: one with hyperkalaemia, one with hypotension and two were non-compliant. Three were discontinued in the placebo group: two were non-compliant and one was diagnosed with obstructive sleep apnoea. Dose up-titration of study drug was done in 72% of the placebo-treated patients (treatment dose at end of study, number of patients: 12.5 mg, n ¼ 0; 25 mg, n ¼ 15; 50 mg, n ¼ 39) and in 57% of spironolactonetreated patients (12.5 mg, n ¼ 10; 25 mg, n ¼ 24; 50 mg, n ¼ 23).
At baseline, all subjects were treated with at least three antihypertensive agents including a diuretic and RAAS-blocking agent, but not MRA. There was no difference in antihypertensive treatment between the placebo-assigned and spironolactoneassigned groups. Baseline use of antihypertensive agents was as follows: angiotensin-converting enzyme inhibitors (ACEi) (51%), angiotensin II receptor blocker (ARB) (37%), dual blockade (12%), b-blocker (45%), calcium channel blocker (84%), other agents (14%), thiazide (77%), loop-diuretics (16%).
Samples for urinary proteomics analysis in the present study were collected at baseline in 111 subjects, of which urine albumin to creatinine ratio (UACR) at both baseline and end were measured in 101 subjects.
Ethical considerations
All participants signed informed consent both for participation in the clinical trial and for biological material to be collected for the purpose of future research. In addition to the original ethics approval (S-20090135), this post hoc analysis was approved as a sub-study by the Ethical Committee in the Southern Region of Denmark (no. 39622). Data was handled anonymously in all statistical analyses.
Proteomics analysis
Urine samples were prepared and capillary electrophoresis mass spectrometry (CE-MS) analysis was performed as previously described [15, 16] . To ensure high-data consistency, a minimum of 800 peptides/proteins had to be detected with a minimal MS resolution of 8000 in a minimal migration time interval of 10 mins. Reference signals of 1770 urinary polypeptides were used for CE-time calibration. For normalization of analytical and urine dilution variances, MS signal intensities were normalized relative to 29 internal standard peptides [17] . All detected peptides were deposited, matched and annotated in a Microsoft SQL database.
CKD273 is a support vector machine-based classification model that allows the classification of samples in the highdimensional parameter space using MosaCluster software (version 1.7.0) [18, 19] . MosaCluster calculated classification scores, based on the amplitudes of the biomarker contained in CKD273. Classification is performed by determining the Euclidian distance of the 273-dimensional vector to a 272-dimensional maximal margin hyperplane [7] . The technicians in the proteomics laboratory were blinded in terms of treatment allocation and endpoints at the time of analysis.
Outcomes
The primary endpoint for this post hoc analysis was defined as percentage change in UACR from baseline to end of treatment. The secondary endpoint was changes in plasma potassium.
Statistics
First, we examined the question of whether CKD273 predicts response to treatment as a continuous variable. Endpoints were estimated with use of a linear mixed model (including period treatment effect and with random intercept). Linear models were used in estimates of interaction in endpoint estimates. To fit model assumptions, UACRs were logarithmically transformed. Adjustment for significant co-variables was included based on forward selection with a significance level of 0.1. Comparison of continuous variables at baseline between treatment groups were based on unpaired t-test and chi-square for categorical variables.
Secondly, we stratified the study population in tertiles of CKD273 scores (lowest tertile is less than À0.232, highest tertile >0.215).
Thirdly, we compared the fraction of responders between treatment groups and between tertiles of CKD273. We defined a 30% reduction in UACR from baseline to end of study as 'responders', as this magnitude of UACR reduction is thought to have clinical significance and has been associated with beneficial long-term outcome [20] [21] [22] . To further investigate the potential use of proteomics we also compared the individual peptides within the proteomics classifier to evaluate differences in single peptides at baseline between responders and nonresponders. Unadjusted Wilcoxon test was used in comparison between groups without correction for multiple testing.
Lastly, as an exploratory analysis we used a specific cut-point in CKD273 (>0.343). Previous publications have used this cutpoint for risk assessment based on CKD273 to identify patients with CKD [7] . In addition, we analysed the ability of CKD273 to predict change in potassium during treatment with spironolactone.
Results with P < 0.05 were considered statistically significant. SAS Enterprise Guide version 7.1 by SAS Institute Inc. (Cary, NC, USA) was used for statistical analysis and R-studio (Version 0.98.1103) was used for graphical layout.
R E S U L T S
Effect of spironolactone and predictive ability of the CKD273 classifier A total of 111 subjects, baseline samples were available and underwent proteomic analyses. There was no significant difference in any of the baseline variables between treatment groups (Table 1) . After 16 weeks treatment of systolic and diastolic blood pressure, eGFR and UACR decreased, and plasma potassium increased with spironolactone treatment compared with placebo (P < 0.012) ( Table 2) . A large between-patient variability in response to spironolactone was observed in all parameters, reflected by the wide 5th to 95th percentile range ( Table 2 ). The mean relative UACR reduction was similar and the betweenpatient variability remained large regardless of the dose of spironolactone [12.5 mg, 63% (5th to 95th percentile, 26-301%); 25 mg, 54% (17-131%); 50 mg, 57% (6-666%)].
A significant interaction was detected between CKD273 score at baseline and treatment assignment (b ¼ À1.09, P ¼ 0.026 for interaction) indicating that higher CKD273 scores were associated with a larger reduction in albuminuria. After adjustment for baseline UACR, the interaction between treatment and CKD273 was not statistically significant (P ¼ 0.12). However, in a multiple regression model, CKD273 (P ¼ 0.0023), baseline UACR (P < 0.001) and treatment group (P ¼ 0.0014) remained independent predictors of treatment response. When treatment groups were separately analysed, baseline CKD273 score was associated with albuminuria changes over 16 weeks (b ¼ À0.70, P ¼ 0.049). In contrast, baseline CKD273 was not associated with albuminuria changes in the placebo group [b ¼ 0.39, P ¼ 0.25; (Figure 1) ] .
Stratification in tertiles of CKD273
After stratification of the study population into tertiles based on CKD273, baseline variables between placebo and spironolactone were similar in each tertile, aside from glycated haemoglobin A1c (HbA 1c ) in the highest tertile (P ¼ 0.034) ( Table 3 ). Only subjects in the highest tertile of CKD273 had a significant relative reduction in UACR during treatment of 63% [95% confidence interval (CI): 35-79%, P ¼ 0.013], 4% (À59 to 42%, P ¼ 0.85) in the middle tertile and 29% (À12 to 55%, P ¼ 0.12) in the lower tertile ( Figure 2 ). In comparison, the highest tertile had a significantly greater reduction in UACR than the other two tertiles combined (P ¼ 0.013). After adjustment for baseline UACR, the predictive ability of the highest tertile was attenuated (P ¼ 0.33). Values are mean reduction from baseline to end of treatment (5th to 95th percentile). In responder subjects, defined as those who had a 30% reduction in UACR from baseline to end of treatment, 62.5% were in the spironolactone-treated group and 36.5% in the placebo group (P ¼ 0.04). When stratified in tertiles based on CKD273 classifier score, the proportion of responders in the placebo and spironolactone group were equal (41 versus 40%, respectively, in the lower and 26 versus 30%, respectively, in the middle tertile; P ¼ 0.64) (Table 4 ). However, in the highest tertile, 75% of subjects who were treated with spironolactone responded with a 30% or greater reduction in UACR compared with 31% in the placebo-treated group (P ¼ 0.009).
In the analysis of individual peptides, 14 of the 273 peptides were significantly different (P < 0.05) between responder and non-responder patients, and all peptides originated from collagen fragments (Figure 3) . The most significant change was seen in collagen alpha-1 (I) chain with a two-fold lower concentration in the non-responder group compared with the responders (P ¼ 0.0045). The highest difference was seen in collagen alpha 2 (I) chain with a five-fold higher concentration in the responder group (P ¼ 0.026).
CKD273 cut-off and MRA response
Using the predefined CKD273 score threshold of 0.343 to stratify the study population, 29 subjects (26%) had a CKD273 value above the threshold. Subjects above the cut-point had higher levels of baseline UACR (22 versus 130 mg/g, P < 0.0001) and potassium (3.8 versus 4.0 mmol/L, P ¼ 0.0026), but did not differ in other baseline variables (data not shown). Subjects above the cut-point had the greatest reduction from baseline in UACR of 58% (95% CI: 30-76%) after spironolactone treatment when compared with subjects below the cutpoint with a reduction of 31% (55 to À5%) (P ¼ 0.005 for difference between reduction in UACR). After adjustment for baseline UACR, the predictive ability of stratification by cut-point (12) 134 (14) 138 (12) 142 (16) 148 (18) 141 (12) Diastolic blood pressure (mmHg)
77 (10) 75 (7) 77 (10) 78 (9) 79 (12) on treatment response was no longer statistically significant (P ¼ 0.09). (3.7-4.0)] (P ¼ 0.27 for heterogeneity). CKD273 did not predict the changes in potassium during treatment with spironolactone when analysed as a continuous variable or stratified in tertiles of CKD273 score (P > 0.97) and there was no interaction between treatment assignment and baseline CKD273 score (P > 0.67). The proportion of subjects below and above the cut-point of CKD273 in each spironolactone dose group was equal (P ¼ 0.87).
CKD273 and change in plasma potassium
D I S C U S S I O N
It is well known that patients show a wide individual variability in the response to drugs, including MRAs such as spironolactone. However, few tools are available for patients with diabetes to predict who would benefit from treatment. Using urinary proteomics we demonstrated in a post hoc analysis of a clinical trial that subjects with type 2 diabetes and resistant hypertension with a high CKD273 score have the highest reduction in UACR during treatment with spironolactone, as an adjunct to RAAS blocking intervention with ACEis or ARBs. This suggests that the modification of proteins and peptides in the urine, as reflected by a higher CKD273 score, renders the patient more receptive to treatment.
We and others have recently demonstrated that patients with type 1 and type 2 diabetes and high levels of the CKD273 have an increased risk of progression from normoalbuminuria to micro-and macroalbuminuria [10, 11, [23] [24] [25] . The ability to identify patients with a high risk of progression in diabetic kidney disease with the use of CKD273 and with the knowledge from our findings, assigning only patients with the highest CKD273 score to MRA treatment, may help tailor therapy to those at greatest risk and those with the best response to treatment. The combination of risk assessment and treatment benefit is currently being tested in a prospective multicentre randomized controlled trial in which patients with high CKD273 scores are randomly assigned to spironolactone or placebo (NCT02040441 [26] ). Results of this study will validate or refute findings of the current study.
Urinary albumin excretion is a consequence of universal vascular damage in patients diagnosed with type 2 diabetes and kidney disease and it is an established clinical hallmark [27, 28] . Clinical trials have shown a beneficial effect on mortality and progression to end-stage renal disease using ACEis or ARBs where albuminuria-lowering effects were evident [29, 30] . Post hoc analyses of other clinical trials have identified the albuminuria-lowering effect to be a good predictor of mortality, and cardiovascular and renal outcomes [31] [32] [33] . Changes in urinary albumin excretion have been and continue to be used as a surrogate endpoint for effect of treatment in studies intervening with MRAs [1, 5, 6, 34, 35] .
The stratified analyses demonstrated the potential for response prediction, which may change future prescription practice and secure a high level of benefit using personalized medicine, where each patient is assessed for treatment response early in the course of treatment. For non-responders this would in turn mean not having to use medication that is not effective, thereby avoiding unnecessary side effects. Boxplot of relative reduction in UACR in the spironolactone treated group stratified by tertiles of baseline CKD273. Lowers tertile 29% (95% Cl: -12 to 55, P ¼ 0.12), Middle tertile 4% (À59 to 42, P ¼ 0.85), 63% (35 to 79%, P ¼ 0.013). In comparison the highest tertile had a greater reduction vs. the middle tertile (P ¼ 0.011) and vs a combination of the lower and middle tertile (P ¼ 0.013). Table 4 . Number of subjects with more than 30% reduction in UACR stratified by tertiles of baseline CKD273 and treatment allocation In our analysis of single peptides, a relatively low level of collagen 1 identified subjects with the greatest reduction in UACR. We acknowledge that this analysis is not corrected for multiple testing and should, therefore, be interpreted carefully. Previous studies have identified increased levels of collagen 1 in the kidney and heart of diabetic mice and human biopsy material and have been linked to fibrosis [12, 36, 37] . Treatment with a RAAS-blocking agent, irbesartan, decreased cardiac collagen 1 in mice [38] . Andersen et al. [39] used the same proteomics classifier to evaluate the treatment effect of angiotensin II receptor in diabetic nephropathy. Several of the peptides identified by Andersen et al. to change during treatment originated from collagen alpha-1 (I) chain as identified in our study; however, none of the fragments is an exact match. One interpretation of our finding is that subjects with relatively low levels of urine collagen may accumulate the collagen in the kidney resulting in fibrosis, leaving them more receptive to anti-fibrotic treatment with mineralocorticoid receptor blockade.
In this study we were not able to identify patients at risk of hyperkalaemia using the proteomics classifier. One explanation for the lack of association may be that we used change in potassium levels from baseline to end of treatment, after 16 weeks, and investigators were allowed to down-titrate the dose of spironolactone in case of hyperkalaemia or even discontinue spironolactone altogether, resulting in lower potassium levels at Week 16. Unfortunately, we have no information on the subject who discontinued due to hyperkalaemia. Another obvious explanation could be that the CKD273 does not predict risk of hyperkalaemia during treatment with spironolactone. The observation that the CKD273 score predicted UACR, but not potassium response to spironolactone suggests that the UACR reduction is not always congruent with a potassium increase, in line with previous findings [1, 24] . This may relate to two distinctly different pathways of MRA treatment effects, one being the glomerular effects, leading to UACR reduction, whereas the mechanism causing hyperkalaemia is likely more associated with effects at a tubular level.
We identified a high fraction of patients in the placebo group with a reduction in albuminuria from baseline to the end of study. The study population included was defined as having resistant hypertension, treated with at least three antihypertensive agents. We cannot rule out a certain study effect, meaning that increased attention and possibly adherence to medication may have influenced UACR levels. In addition, UACR measurements at both baseline and end-of-study were carried out as single-morning spot collections, which carries with it a certain degree of variability. Other limitations include the post hoc nature of the analysis and a highly selected study population (type 2 diabetes and resistant hypertension).
Urinary proteomics represents one of several new technologies that have the potential for personalizing drug treatment. The benefit of using additional deep phenotyping such as proteomics to optimize treatment should always be viewed in the light of cost of the analysis, and prior to clinical use cost- Fold difference:
FIGURE 3: Analysis of individual peptides in patients with more than 30% reduction in UACR (responders), compared to less than 30% reduction (non-responders). Amplitude measurements of specific peptides. Fold difference calculated in differences of means between responders and non-responders for each peptide (negative value eques highest amplitude in non-responders). P-value originates from unadjusted Wilcoxon test. For each peptide the amplitude of measurement is display for responders in first column and non-responders in second column. effectiveness analysis should be performed. Future investigations using deep phenotyping, combined with assessment of treatment response, may not only help develop new targets for intervention, it may also, as in our study, provide the opportunity for revival of off-patent agents, e.g. spironolactone.
C O N C L U S I O N
We demonstrate the ability of a proteomic classifier to identify patients with the highest treatment responses, as judged by reduction in UACR, in a population diagnosed with type 2 diabetes and resistant hypertension. Our finding implies that urinary proteomics may be a valuable tool to tailor therapy and to identify patients who will benefit from MRA treatment, but confirmation in larger studies is needed. 
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